Navigation Links
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

ated expenses.  The lower costs also resulted from higher prior year expenses associated with preparation for the June 2009 FDA Advisory Committee meeting for KRYSTEXXA, coupled with the wind down of the open label extension clinical trial for KRYSTEXXA.  

Selling, general and administrative expenses decreased $5.8 million, or 19%, to $25.0 million for the year ended December 31, 2010, from $30.8 million for the year ended December 31, 2009.  The decrease was partially due to lower marketing costs, which included $2.1 million of lower expenses associated with the preparation for a possible commercial launch of KRYSTEXXA in 2009 and a decrease of $2.3 million in compensation related and severance expenses.

Other expense, net increased $5.2 million, or 43%, to $17.3 million for the year ended December 31, 2010 as compared to $12.1 million for the year ended December 31, 2009, primarily due to the variance in non-cash mark-to-market valuation adjustments to the Company's warrant liability in 2010 versus the prior year.

Conference CallSavient's management team will host a live conference call and webcast on Friday, February 25, 2011 at 9:00 a.m. Eastern Time to review the fourth quarter and year-end 2010 financial results.  To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International).  The conference identification number is 45733606.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on February 25, 2011 through 11:59 p.m. Eastern Time on March 11, 2011 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
2. Savient Closes Sale of $230 Million in Convertible Senior Notes
3. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
4. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
6. Savient Pharmaceuticals Announces Search for CEO
7. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
10. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
11. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) ... of Understanding ("MOU") with LaurelCo, LLC, an Illinois ... of both cultivation and dispensary medical marijuana licenses in the ... MOU, GBLX will acquire a 20% equity interest in LaurelCo, ... TM growing chambers, as well as all technology related ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Helen Londe, M.D. Contributing Editor The first human case of ... occurred in Kansas in late June. The CDC has ... being 2005's first documented incidence of the mosquito borne disease ... about 11 kb. It primarily infects birds and mosquitoes, ...
... lipids, comprised of triglycerides and cholesterols, vary with genetic ... factors contribute to serum cholesterol and triglyceride levels and ... events. Perhaps no other commonly determined medical laboratory values ... levels of good, bad, and total cholesterol, making the ...
Cached Medicine Technology:West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 2West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 3West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak 4Analyzers Offer Point-of-Care Lipid Panels 2Analyzers Offer Point-of-Care Lipid Panels 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 As health ... are looking to private exchanges. “Private Exchange Strategies ... 6 webinar from Atlantic Information Services, will provide answers ... exchange strategies for the future. , Barbara Gniewek, Jonathan ... with extensive experience in the private exchange sector — ...
(Date:7/28/2014)... According to the Heartburn No More PDF review recently ... help people get rid of acid reflux naturally. ... heartburn and acid reflux. In addition, inside this book, people ... factors for reflux disease. , Vkool informs in its ... symptoms of reflux disease naturally without medications. The book also ...
(Date:7/28/2014)... 28, 2014 Building a sense of ... important. Where personal outdoor space is not possible, ... enjoy fun and exercise outside is important. That’s ... in quality commercial playground equipment from APCPLAY. , Old ... Midlothian, Virginia. It is an historic tourist location of ...
(Date:7/28/2014)... Calif., July 27, 2014 - (PRWEB) July 28, 2014 ... in 12 months by earning the Masters Champion title at ... proving that age is no obstacle for this athlete. She ... at the event hosted by the International Pole Sports Federation ... 63, traveling from 30 countries, took part in the competition. ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the ... Feelings.” The new book, DOC X MD Funny Feelings ... story telling style with humor and medical accuracy. The book ... will find answers to those age-old questions that most folks ... pee? Why do mosquitoes bite some and not others? Why ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... Texas Pesticides and pollutants are related to an alarming ... anencephaly in rural China, according to scientists at The University ... of the pesticides found in high concentrations in the placentas ... Endosulfan is only now being phased out in the United ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Oct. ... friends tend to have areas of the brain that ... with fewer friends, British researchers say. "We were ... in them is reflected in brain structure and function," ...
... cardiac arrest is the leading cause of death in the ... initial collapse. In addition, fewer than half of the small ... the hospital, because they often suffer irreversible brain damage. A ... Neurology provides guidance to physicians using therapeutic cooling to ...
... flushes and night sweats years after the menopause finds a new ... and Gynaecology . Hot flushes and night sweats (HF/NS) are ... severity and duration vary considerably. The average age of ... it is generally assumed that HF/NS last between 2 to 5 ...
... Spanish . Researchers from Massachusetts General ... cell mechanism activated by a protein HOXB9 that becomes an ... world continue to focus their research on breast cancer. As ... growing, as well as of their interactions with the microenvironment. ...
... Duke University Medical Center researchers have verified data that ... a patient who has been under anesthesia for an operation. ... first year after surgery if a patient has low values ... patients whose values are all normal. The three ...
Cached Medicine News:Health News:Study links pollutants to a 450 percent increase in risk of birth defects 2Health News:Study links pollutants to a 450 percent increase in risk of birth defects 3Health News:More Facebook Friends, More Gray Matter in Brain? 2Health News:More Facebook Friends, More Gray Matter in Brain? 3Health News:Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients 2Health News:Older women still suffer from hot flushes and night sweats years after the menopause finds study 2Health News:Discovery of a cell mechanism that reduces effectiveness of breast cancer treatment 2Health News:3 factors could point to your fate after surgery 2
... The proper gel is essential ... when working with pH catheters ... specific chloride ion concentration in ... required for proper function of ...
The WaveMax is one of the most flexible stainless steel stents due to its unique wave design and has the lowest effective profile, accommodating a 6F sheath up to 7 mm....
... its specifically designed reagents, allows to ... sample, multiple analytes. This unique technology ... laboratories willing to simplify and standardize ... as well as to reduce as ...
... a variety of applications across a broad ... is suitable for any laboratory demanding high ... mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per hour ... range of chromogenics, the AMAX DestinyPlus is ...
Medicine Products: